AU Patent

AU2010224184A1 — Pyrrolo [2, 3-b] pyridine derivatives for the inhibition of Raf kinases

Assigned to Plexxikon Inc · Expires 2011-09-29 · 15y expired

What this patent protects

N-[3-(4-Cyano-l H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-4- trifluoromethyl-benzenesulfonamide, N-[3-(4-ethynyl-lH-pyrrolo[2,3-b]pyridinc-3-carbonyl)- 2,4-difluoro-phenyl]-4-trifluoromethyl-benzenesulfonamide, and salts thereof, formulations thereof, conjugates t…

USPTO Abstract

N-[3-(4-Cyano-l H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-4- trifluoromethyl-benzenesulfonamide, N-[3-(4-ethynyl-lH-pyrrolo[2,3-b]pyridinc-3-carbonyl)- 2,4-difluoro-phenyl]-4-trifluoromethyl-benzenesulfonamide, and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one Raf protein kinase. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of Raf protein kinases, including pain and polycystic kidney disease.

Drugs covered by this patent

Patent Metadata

Patent number
AU2010224184A1
Jurisdiction
AU
Classification
—
Expires
2011-09-29
Drug substance claim
No
Drug product claim
No
Assignee
Plexxikon Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.